Insider trade

Officer sold ~$426K of UTHR shares in the open market

Traded Jul 16, 2026 · Filed Jul 17, 2026

Why it stands out

United Therapeutics's & GENERAL COUNSEL sold $426K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Officer$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$426,352

Shares × reported transaction price

Timing vs results

71 days after results of May 6, 2026, 20 days before results of Aug 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	−1.3%	−0.6%	−0.8%
30 days	−5.1%	+4.0%	−9.0%

Past results only. Not a forecast.

This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
This transaction was executed in multiple trades at prices ranging from $532.51 to $533.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Filed 8w ago

Traded Aug 13 · filed 2 days later

Derivative exercise or conversion — not an open-market buy.

Scheduled in advanceFiled 8w ago

Scheduled in advanceFiled 8w ago